Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.

Takafumi Yanagisawa; Tatsushi Kawada; Pawel Rajwa; Hadi Mostafaei; Reza Sari Motlagh; Fahad Quhal; Ekaterina Laukhtina; Frederik König; Maximilian Pallauf; Benjamin Pradere; Pierre I Karakiewicz; Peter Nyirady; Takahiro Kimura; Shin Egawa; Shahrokh F Shariat

doi:10.1016/j.urolonc.2022.06.018

Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.

Takafumi Yanagisawa, Tatsushi Kawada, Pawel Rajwa, Hadi Mostafaei, Reza Sari Motlagh, Fahad Quhal, Ekaterina Laukhtina, Frederik König, Maximilian Pallauf (Co-author), Benjamin Pradere, Pierre I Karakiewicz, Peter Nyirady, Takahiro Kimura, Shin Egawa, Shahrokh F Shariat

Department of Urology and Andrology

Research output: Contribution to journal › Review article › peer-review

13 Citations (Web of Science)

Original language	English
Pages (from-to)	177-191
Journal	UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS
Volume	41
Issue number	4
DOIs	https://doi.org/10.1016/j.urolonc.2022.06.018
Publication status	Published - 2023

Keywords

OPEN-LABEL
ANDROGEN RECEPTOR
JAPANESE PATIENTS
SURVIVAL
MEN
MITOXANTRONE
ABIRATERONE
PREDNISONE
THERAPY
MODEL

Access to Document

10.1016/j.urolonc.2022.06.018

Cite this

Yanagisawa, T., Kawada, T., Rajwa, P., Mostafaei, H., Motlagh, R. S., Quhal, F., Laukhtina, E., König, F., Pallauf, M., Pradere, B., Karakiewicz, P. I., Nyirady, P., Kimura, T., Egawa, S., & Shariat, S. F. (2023). Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis. UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS, 41(4), 177-191. https://doi.org/10.1016/j.urolonc.2022.06.018

@article{c21ce21e04eb482db730c2c99aea4b4d,

title = "Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.",

keywords = "OPEN-LABEL, ANDROGEN RECEPTOR, JAPANESE PATIENTS, SURVIVAL, MEN, MITOXANTRONE, ABIRATERONE, PREDNISONE, THERAPY, MODEL",

author = "Takafumi Yanagisawa and Tatsushi Kawada and Pawel Rajwa and Hadi Mostafaei and Motlagh, \{Reza Sari\} and Fahad Quhal and Ekaterina Laukhtina and Frederik K{\"o}nig and Maximilian Pallauf and Benjamin Pradere and Karakiewicz, \{Pierre I\} and Peter Nyirady and Takahiro Kimura and Shin Egawa and Shariat, \{Shahrokh F\}",

note = "Pallauf: Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria",

year = "2023",

doi = "10.1016/j.urolonc.2022.06.018",

language = "English",

volume = "41",

pages = "177--191",

journal = "UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS",

issn = "1078-4139",

publisher = "Elsevier ",

number = "4",

}

Yanagisawa, T, Kawada, T, Rajwa, P, Mostafaei, H, Motlagh, RS, Quhal, F, Laukhtina, E, König, F, Pallauf, M, Pradere, B, Karakiewicz, PI, Nyirady, P, Kimura, T, Egawa, S & Shariat, SF 2023, 'Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.', UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS, vol. 41, no. 4, pp. 177-191. https://doi.org/10.1016/j.urolonc.2022.06.018

Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis. / Yanagisawa, Takafumi; Kawada, Tatsushi; Rajwa, Pawel et al.
In: UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS, Vol. 41, No. 4, 2023, p. 177-191.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.

AU - Yanagisawa, Takafumi

AU - Kawada, Tatsushi

AU - Rajwa, Pawel

AU - Mostafaei, Hadi

AU - Motlagh, Reza Sari

AU - Quhal, Fahad

AU - Laukhtina, Ekaterina

AU - König, Frederik

AU - Pallauf, Maximilian

AU - Pradere, Benjamin

AU - Karakiewicz, Pierre I

AU - Nyirady, Peter

AU - Kimura, Takahiro

AU - Egawa, Shin

AU - Shariat, Shahrokh F

N1 - Pallauf: Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria

PY - 2023

Y1 - 2023

KW - OPEN-LABEL

KW - ANDROGEN RECEPTOR

KW - JAPANESE PATIENTS

KW - SURVIVAL

KW - MEN

KW - MITOXANTRONE

KW - ABIRATERONE

KW - PREDNISONE

KW - THERAPY

KW - MODEL

U2 - 10.1016/j.urolonc.2022.06.018

DO - 10.1016/j.urolonc.2022.06.018

M3 - Review article

C2 - 35970698

SN - 1078-4139

VL - 41

SP - 177

EP - 191

JO - UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS

JF - UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS

IS - 4

ER -